Bridge Health
← Back to BlogMay 4, 2026

What ICH Q13 Actually Requires — And What It Doesn’t

ICH Q13 gets treated as a checklist, but it’s a lifecycle framework. Here’s what the guideline actually mandates versus what teams assume it does, and where that gap causes avoidable delays.

ICH Q13 is the first internationally harmonized guideline written specifically for continuous manufacturing, and since its adoption teams have tended to treat it as a checklist: control strategy document, residence time distribution study, diversion criteria, done. That reading misses the point of the guideline and creates real risk in submissions.

Q13 is a lifecycle framework, not a specification. It does not prescribe a fixed set of process analytical technologies, a required batch definition, or a mandated control strategy architecture. What it requires is that a sponsor can demonstrate — with data, not narrative — that material moving through a continuous process has been tracked, characterized, and controlled well enough to support a release decision with the same confidence a batch process would provide.

The three requirements that actually matter are control strategy justification, state of control demonstration, and traceability. Control strategy justification means explaining why the chosen combination of in-process controls, real-time release testing, and end-product testing is sufficient for the specific process — not adopting a generic template. State of control means the process has documented evidence, typically statistical, that it operates within defined limits over the run duration claimed, including startup and shutdown transients. Traceability means every unit of output can be traced back to the process conditions and material inputs that produced it, which is what makes diversion of non-conforming material possible without discarding an entire run.

Where teams lose time is in over-engineering the residence time distribution study before the control strategy is settled, or building a diversion protocol around equipment capability rather than the actual risk profile of the product. Q13 rewards a control strategy that is proportionate to risk and defensible with data — not the most sophisticated one available.

The practical implication for a development program: sequence the RTD and traceability work after the control strategy rationale is drafted, not before. It's far easier to design the data collection plan once you know what claim you're trying to support.